Abstract 59MO
Background
Penpulimab is a novel humanized IgG1 mAb that blocks PD-1 binding to PD-L1, engineered to eliminate FcγR binding and ADCC/ADCP completely.
Methods
AK105-302 is a 1:1 randomized, double-blind, placebo-controlled, multicenter, phase III trial to compare penpulimab or placebo plus carboplatin and paclitaxel as first-line treatment for locally advanced or metastatic squamous NSCLC. The stratification factors included PD-L1 and gender. Eligible pts were randomized 1:1 to receive penpulimab 200 mg or placebo plus chemotherapy every 3 weeks for four cycles, followed by penpulimab or placebo as maintenance therapy until disease progression or 24 months, subjects in placebo group may choose to cross over to open-label penpulimab monotherapy for up to 24 months. The primary endpoints were PFS in the ITT population and in the PD-L1-positive population (TPS of PD-L1≥1%), assessed by an IRRC. The secondary endpoints were OS, ORR, DoR, DCR and TTR.
Results
175 pts were assigned to penpulimab plus chemotherapy (P+C) and 175 to placebo plus chemotherapy (C). At data cutoff (Jun 1, 2022), the median follow-up was 23.56m. The mPFS by IRRC was significantly longer with P+C than with C (7.6m vs. 4.2m; HR 0.44, 95%CI: 0.34-0.56; p < 0.0001), 12m-PFS rate (37.1% vs. 9.2%) and 24m-PFS rate (23.8% vs. 5.9%) were significantly higher in P+C than C. In the PD-L1-positive population, the mPFS by IRRC was also significantly longer with P+C than with C (8.1m vs. 4.2m; HR 0.37, 95%CI: 0.27-0.51; p < 0.0001). The mOS of P+C was not reached, but the benefit trend was obvious (NR vs. 19.8m; HR 0.55, 95%CI: 0.40-0.75; p = 0.0002), 24m-OS rate (61.1% vs. 41.6%) were significantly higher in P+C than C. ORR by IRRC was 71.4% in P+C and 44.0% in C. Treatment with P+C was associated with more durable response (mDoR by IRRC: 8.25m vs 2.96m) than C. Grade ≥3 TRAEs occurred in 63.6% (P+C) vs. 62.9% (C). Serious TRAEs occurred in 28.3% (P+C) vs. 26.9% (C). TRAEs led to treatment discontinuation were 5.2% in P+C and 3.4% in C.
Conclusions
These positive data will support penpulimab plus chemotherapy may be a promising and safe first-line treatment for locally advanced or metastatic squamous NSCLC.
Clinical trial identification
NCT03866993.
Legal entity responsible for the study
Chai Tai Tianqing Pharmceutical Group Co, Ltd. Akeso Tiancheng, Inc.
Funding
Chai Tai Tianqing Pharmceutical Group Co,Ltd. Akeso Tiancheng, Inc.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
35MO - Number of IL-2 doses and clinical outcomes of tumor-infiltrating lymphocyte (TIL) cell therapy: Post hoc analysis of the C-144-01 trial of lifileucel in patients with advanced melanoma
Presenter: Jessica Hassel
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
36MO - Location and size of metastasectomy in melanoma patients treated with tumor-infiltrating lymphocytes (TIL) in relation to clinical outcome
Presenter: Maartje Rohaan
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
LBA6 - UCPVax therapeutic vaccination promotes cytotoxic and Th1 polarized antitumor CD4 T cells and epitope spreading in patients with advanced non-small cell lung cancer
Presenter: Olivier Adotevi
Session: Mini Oral session 1
Resources:
Abstract
Slides
LBA2 - Phase II study of PD-L1 Expression Guidance on Neoadjuvant (NA) Nivolumab (Nivo) Monotherapy with or without platinum-doublet Chemotherapy in Resectable NSCLC
Presenter: Si-Yang Liu
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
122MO - Cemiplimab (cemi) + platinum doublet chemotherapy (chemo) + ipilimumab (ipi) for first-line treatment of advanced non-small cell lung cancer (NSCLC): EMPOWER-Lung 3 part I
Presenter: Ana Baramidze
Session: Mini Oral session 1
Resources:
Abstract
60MO - Real-World Overall and Progression-Free Survival for First-Line Immunotherapy-Based Regimens in Advanced Non-small Cell Lung Cancer
Presenter: David Waterhouse
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
61MO - IMscin001 (Part 2: Randomized Phase III): Pharmacokinetics (PK), efficacy and safety of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC)
Presenter: MAURICIO BUROTTO PICHUN
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant
Presenter: Luca Mazzarella
Session: Mini Oral session 1
Resources:
Slides
Webcast
Invited Discussant
Presenter: Benjamin Besse
Session: Mini Oral session 1
Resources:
Slides
Webcast